A CLINICIAN'S COMMENTS ON THE CYCLOPHOSPHAMIDE HEMATOTOXICITY BIOLOGICALLY BASED RISK ASSESSMENT MODEL
暂无分享,去创建一个
[1] M. Petri,et al. Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease , 1998, Annals of Internal Medicine.
[2] F. Appelbaum,et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.
[3] J. Reems,et al. Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] L. Grochow,et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[5] M. Fackler,et al. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. , 1996, Blood.
[6] Richard J. Jones,et al. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. , 1996, Blood.
[7] R. Gray,et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Cox. Simple relations between administered and internal doses in compartmental flow models. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.
[9] L. Grochow,et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. , 1995, Cancer research.
[10] M. Kastan,et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. , 1990, Blood.
[11] J. Adamson,et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. , 1987, The New England journal of medicine.
[12] Janice,et al. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. , 1987, Blood.
[13] R. Brookmeyer,et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. , 1985, Blood.
[14] T M Fliedner,et al. A mathematical model of canine granulocytopoiesis , 1980, Journal of mathematical biology.
[15] L. Grochow,et al. Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.